ECPC Funding 2015

Revenue and results for 2015

For the financial year 2015, the revenue from different sources amounted to a total of € 682.912. Costs and expenses for Board, personnel, projects, awareness and advocacy came to a total of € 505.173, leaving a positive balance of € 163.831.

The different sources of revenue can be broken down in the following main areas:
  • Pharmaceutical companies;
  • European Commission – for several multi-year projects;
  • Various organisations –NGOs and Foundations;
  • Revenue from other sources – subletting office space, reimbursements and donations.
 

Acknowledgements

ECPC gratefully acknowledges the generous support of the following contributors in 2015:

Not-for-Profit Organisations and Public Entities


 

Five Top Corporate Donors

 


 

Other pharmaceutical companies (listed in alphabetical order)

Revenue breakdown

Revenue for 2015 has come mostly from pharmaceutical companies’ grants, since payment is done (most of the time) within a short period of time, making it possible for ECPC to pay its staff, suppliers and office/maintenance costs.

SOURCE OF REVENUE AMOUNT PERCENTAGE

EU-funded Projects

€ 63.629 9.32%
  • eSmart
  • € 5.715
 
  • RARECAREnet
  • € 48.164
 
  • EuroCan Platform
  • € 9.753
 

Organizations

€ 35.000 5.13%
  • Brain Tumour Charity
  • € 15.000
    • Policy
    • € 15.000
  • Lung Cancer Europe (LuCE)
  • € 10.000
    • Conference in the European Parliament
    • € 10.000
  • CDDF
  • € 10.000
    • IOP
    • € 10.000

Waldesian Church

€ 50.000 7.32%
  • Cancer Advocacy Academy
  • € 50.000

Miscellaneus revenue

€ 20.898 3.06%
  • Reimbursements
  • € 10.708
  • Donations from sports events
  • € 990
  • Exceptional income (speaker fees)
  • € 800
  • Revenue from subletting office space
  • € 8.400
TOTAL NON-INDUSTRY REVENUE
€ 169.527
 

Grants from pharmaceuticals

  75.18%
  • IOP
  • € 155.000
  • AGM
  • € 91.000
  • Policy
  • € 30.000
  • Bladder Project
  • € 22.300
  • Nutrition
  • € 80.000
  • ECPC Action Plan
  • € 110.000
  • Infographic on biomarkers
  • € 20.000
  • Other donations
  • € 5.085
TOTAL INDUSTRY REVENUE
€ 513.385

Expenses breakdown

EXPENSES 2014 2015 DIFFERENCE RATIO

Staff

€ 176.278 € 189.661 € 13.383 +7,6%
  • Gross salaries
  • € 119.869
  • € 128.969
    • Employee Contributions
    • € 22.916
    • € 24.656
    • Net salaries
    • € 96.953
    • € 104.314

Office

€ 63.889 € 69.809 € 5.920 +9,3%
  • Office rent & maintenance
  • € 43.885
  • € 40.127
  • Energy consumption
  • € 1.988
  • € 1.524
  • Office supplies
  • € 1.985
  • € 2.351
  • IT maintenance &
  • € 1.985
  • € 2.351
  • Telephone & internet
  • € 4.392
  • € 3.062
  • Website costs
  • € 4.071
  • € 2.003
  • Fee subscriptions
  • € 1.190
  • € 2.504
  • Other office costs (printing, coffee machine, postage, etc.)
  • € 1.293
  • € 3.645
  • Special costs made to transfer ECPC from NL to BE
  • n/a
  • € 9.685

Board

€ 29.691 € 28.037 € -1.645 -5,6%
  • Board travel
  • € 26.298
  • € 10.066
  • Board travel advocacy
  • € 11.740
  • Audit Committee (travel & lodging)
  • € 1.382
  • Other (subsistence, communication costs, catering, etc.)
  • € 2.011
  • € 6.231

Awareness

€ 62.663
  • IOP, Make Sense Campaign, Nutrition, Get Tested Campaign
  • € 62.663

Advocacy

€ 122.187
  • AGM
  • € 80.325
  • Advocacy
  • € 31.445
  • Staff travels advocacy
  • € 6.897
  • EU lobby for policy
  • € 3.520

EU funded Projects

€ 83.600 € 32.816 n/a n/a
  • Project travel
  • € 36.132
  • € 13.094
  • Project publications
  • € 3.809
  • € 2.948
  • Project conferences &catering
  • € 29.103
  • € 3.662
  • Other project expenses
  • € 10.213
  • € 13.112
TOTAL EXPENSES
€ 352.295 € 505.173 € 151.878 +42%
 
RESULT
€ -42.081 € 163.831

Industry funding

Industry funding in 2015 contributed to 75,18% of the total income

REVENUE FROM INDUSTRY FUNDING AMOUNT PERCENTAGE

Merck

€ 86.000 16.75%
  • Make Sense Campaign / Get Tested Campaigns
  • € 35.000
  • IOP
  • € 31.000
  • Infographic on biomarkers
  • € 20.000

Pfizer

€ 74.000 14.41%
  • IOP
  • € 31.000
  • AGM
  • € 13.000
  • Policy
  • € 30.000

Roche

€ 47.300 9.21%
  • ECPC Action Plan
  • € 35.000
  • Project on Bladder Cancer
  • € 10.000
  • Informal Bladder meeting
  • € 2.300

MSD

€ 41.000 7,99%
  • IOP
  • € 31.000
  • AGM
  • € 10.000

BMS

€ 36.000 7.01%
  • IOP
  • € 31.000
  • AGM
  • € 5.000

Astra Zeneca

€ 36.000 7,01%
  • IOP
  • € 31.000
  • AGM
  • € 5.000

Helsinn

€ 35.085 6.83%
  • Nutrition
  • € 30.000
  • Charity donation
  • € 5.085
  • AGM
  • € 5.000

Baxter

€ 35.000 7,01%
  • Nutrition: Phase 1 - Survey
  • € 15.000
  • Nutrition: Phase 2 - Report
  • € 20.000

Novartis

€ 30.000 5.84%
  • ECPC Action Plan
  • € 30.000
  • AGM
  • € 5.000

Lilly

€ 28.000 5,45%
  • Nutrition
  • € 15.000
  • AGM
  • € 13.000

Amgen

€ 20.000 3,9%
  • ECPC Action Plan
  • € 10.000
  • AGM
  • € 10.000
  • AGM
  • € 5.000

Ipsen

€ 15.000 2,92%
  • Bladder Project
  • € 10.000
  • AGM
  • € 5.000

Boehringer Ingelheim

€ 13.000 2,53%
  • AGM
  • € 13.000
  • AGM
  • € 5.000

Celgene

€ 10.000 1,95%
  • AGM
  • € 10.000

ABBVIE

€ 5.000 0,97
  • AGM
  • € 5.000
  • AGM
  • € 5.000

Sirtex

€ 2.000 0,39%
  • AGM
  • € 2.000
TOTAL FUNDING FROM INDUSTRY
€ 513.385